Century Therapeutics Inc Cash Flow Conversion Efficiency
Century Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Century Therapeutics Inc (IPSC) has a cash flow conversion efficiency ratio of -0.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.85 Million) by net assets ($232.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Century Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Century Therapeutics Inc from 2015 to 2025. This chart illustrates how Century Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Century Therapeutics Inc stock quote for real-time trading data and today's change.
Century Therapeutics Inc Cash Flow Conversion Ratio Explained
Century Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Century Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Century Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is Century Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sky Harbour Group Corp
NYSE MKT:SKYH
|
-0.012x |
|
WONIK Materials Co.Ltd
KQ:104830
|
0.029x |
|
Beijing Airport High-Tech Park Co Ltd
SHG:600463
|
0.008x |
|
Tianjin Hi-Tech Development Co Ltd
SHG:600082
|
0.317x |
|
Osprey Acquisition Corp. III Class A Ordinary Shares
NASDAQ:OSPR
|
N/A |
|
Cantor Equity Partners II, Inc.
NASDAQ:CEPT
|
N/A |
|
Eaton Vance Senior Floating Rate Closed Fund
NYSE:EFR
|
0.098x |
|
Sunny Friend Environmental Technology Co Ltd
TW:8341
|
0.075x |
Annual Cash Flow Conversion Efficiency for Century Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Century Therapeutics Inc from 2015 to 2025. Review Century Therapeutics Inc (IPSC) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $158.94 Million | $-103.88 Million | -0.654x | +4.24% |
| 2024-12-31 | $161.36 Million | $-110.14 Million | -0.683x | -42.73% |
| 2023-12-31 | $184.75 Million | $-88.35 Million | -0.478x | -1130.25% |
| 2022-12-31 | $302.74 Million | $14.05 Million | 0.046x | +120.66% |
| 2021-12-31 | $396.24 Million | $-89.00 Million | -0.225x | -157.92% |
| 2020-12-31 | $-106.41 Million | $-41.27 Million | 0.388x | +120.34% |
| 2019-12-31 | $-91.86 Million | $-16.17 Million | 0.176x | -39.30% |
| 2015-12-31 | $359.71 Million | $104.30 Million | 0.290x | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more